Skip to main content

Viloxazine (Qelbree): A Faster Strattera?

On April 2, 2021, viloxazine, brand name Qelbree, received FDA approval for the treatment of ADHD in children and adolescents ages 6-17 years old. The latest issue of The Carlat Child Psychiatry Report includes a News of Note covering this newly approved medication for ADHD. In this podcast, we discuss the advantages and disadvantages of viloxazine for children and adolescents with ADHD.

https://www.thecarlatreport.com/podcast/viloxazine-qelbree-a-faster-strattera-2/

 

Author
Joshua Feder, M.D. Dr. Feder's Blog

You Might Also Enjoy...

Foundations for a Peaceful World

This week we are launching a new book at the United Nations General Assembly with the voices of multiple countries impacted by armed conflict, some on different sides in the same region, all committed to helping all the children.

Recognizing and Treating Psychosis in Autism

Is it autism, psychosis or both? Autistic traits and psychotic symptoms can look alike. How common is psychosis in autism? Can we differentiate co-occurring autistic traits from psychotic symptoms? Dr. Kristin Cadenhead helps us sort it out.

Autism and Medication: Dr Feder's New Algorithm!

This is part 2 because there is a new Child Medication Fact Book for Psychiatric Practice, Second Edition that just came out. Dr. Feder is here to tell us the purpose of the book and to walk us through his new algorithm for supporting autistic kids.